Prometheus Laboratories has launched the first serogenetic test that can predict a patient’s risk of developing Crohn’s disease complications.

Prometheus’s Crohn’s prognostic test uses six serologic markers and three genetic markers to provide the physicians with a personalised serogenetic profile for each patient.

The test will enable physicians to quantify patients based on their risk of developing disease complications, and would assist them in determining optimal treatment strategies.

Director of the IBD Pediatric Center at Cedars Sinai Medical Center in Los Angeles Marla Dubinsky said the test may help physicians develop a more individualised treatment plan for each patient and help them explain the risk / benefit ratio of these treatments to their patients and their families.

Crohn’s disease is a chronic disorder that involves inflammation of the digestive / gastrointestinal track, and an estimated 400,000 and 600,000 individuals in North America are affected by this disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.